Novogen (ASX:NRT; NASDAQ:NVGN) signs licensing deal with Genentech

Novogen (ASX:NRT; NASDAQ: NVGN) CEO Dr. James Garner talks about its licensing deal with Genentech for a drug development candidate for glioblastoma, one of the most common and aggressive forms of brain cancer.